Senior figure joins Yorkshire firm which is helping tackle obesity crisis

OptiBiotix Health, a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, has made a senior appointment.

The announcement has been made to the stock exchange.

OptiBiotix Health has appointed René Kamminga as Chief Executive Officer of OptiBiotix Ltd, a wholly owned subsidiary of OptiBiotix Health plc.

OptiBiotix Ltd contains OptiBiotix's SlimBiome, SweetBiotix, and microbiome modulating technology platforms.

Sign up to our Business newsletter

Sign up to our Business newsletter

In a statement, the company said: "The company also announces the change of role of Dr Fred Narbel who will move from his position as director on the OptiBiotix board and managing director of the functional fibres division within OptiBiotix Ltd to a more strategic role as Non-Executive Director of OptiBiotix Ltd.

"René has more than 25 years' experience in the sale of speciality ingredients and products and joins from the position of Vice President of Business Development and Chief Commercial Officer of the Nutraceuticals division of KD Pharma Group. KD Pharma sell high purity Omega-3 APIs and concentrates to both the pharmaceutical and nutraceutical industries and has rapidly become one of the world's largest Omega-3 and fish oil refiners and suppliers in the world."

Stephen O'Hara, CEO of OptiBiotix, commented: "René's experience and track record of growing sales and his network of new industry contacts within pharmaceutical and nutraceutical industries, will help OptiBiotix in its next phase of evolution."